Global CRO Quintiles ($Q) is reaching out to software provider OmniComm to replace its Phase I eClinical technology, signing a 5-year deal with the Florida company.
Under the agreement, Quintiles' Early Clinical Development unit will adopt OmniComm's TrialOne offering, part of a companywide effort to standardize its Phase I clinics on the latest technology. Quintiles' move comes after a thorough evaluation of available software, OmniComm said, and TrialOne won out thanks to its ease of use and interoperability with Infosario, the CRO's analytics platform.
OmniComm's electronic data capture technology allows its clients to pull results from any location with Internet access, ideal for a sprawling outfit like Quintiles, with clinics in more than 100 countries, the company said.
For OmniComm, Quintiles is the latest--and biggest--name to join its roster of life sciences partners, which also includes the CROs Clinverse and Inflamax alongside a host of biotech and pharma outfits. Last month, the Fort Lauderdale company hit a milestone, announcing that its technology had been used in 4,000 completed or in-progress clinical trials.
Quintiles, the world's largest CRO, cleared a record $1 billion in service revenue last quarter, thanks to a more than 10% jump in its product development arm. The company is expecting service revenue to come in between $4.1 billion and $4.2 billion in 2014, amounting to as much as 9% growth.
- read the statement